// PATHOLOGY Questions
// Auto-generated from questions.ts
// Total Questions: 17

import { Question } from '../types';

export const questions: Question[] = [
{
    id: "neet-pg-2024-3",
    subjectId: "pathology",
    chapterId: "neet-pg-2024",
    question: "Which tumor is positive for TTF-1?",
    options: [
      "Squamous Cell Carcinoma (Sq)",
      "Small Cell Carcinoma (Small)",
      "Adenocarcinoma (Adeno Ca)",
      "Carcinoid"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Adenocarcinoma (Option C)**\n\nüî¨ DETAILED EXPLANATION:\n\n**TTF-1 (Thyroid Transcription Factor-1)**, also known as **NKX2-1**, is a **nuclear transcription factor** that serves as a critical **immunohistochemical marker** in the diagnosis of lung tumors.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå TTF-1 EXPRESSION IN LUNG TUMORS:\n\n‚òÖ **ADENOCARCINOMA** ‚≠ê‚≠ê‚≠ê (CORRECT ANSWER)\n  ‚Üí TTF-1 positive in **75-80%** of cases\n  ‚Üí **MOST COMMON TTF-1 positive tumor**\n  ‚Üí Strong nuclear staining pattern\n  ‚Üí Used to differentiate from other primaries\n\n‚Ä¢ **Small Cell Lung Carcinoma (SCLC)**\n  ‚Üí TTF-1 positive in **85-90%** of cases\n  ‚Üí Also strongly positive but less common tumor\n\n‚Ä¢ **Squamous Cell Carcinoma**\n  ‚Üí TTF-1 **NEGATIVE** in >95% of cases\n  ‚Üí Uses **p40/p63** markers instead\n\n‚Ä¢ **Large Cell Carcinoma**\n  ‚Üí TTF-1 positive in only **10-20%**\n  ‚Üí Variable and unreliable\n\n‚Ä¢ **Carcinoid Tumors**\n  ‚Üí TTF-1 **usually NEGATIVE**\n  ‚Üí Rare exceptions\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ IMMUNOHISTOCHEMISTRY PANEL:\n\n**ADENOCARCINOMA Profile:**\n\n‚úÖ **TTF-1 (+)** - Most specific marker ‚≠ê\n‚úÖ **Napsin A (+)** - 80% sensitivity\n‚úÖ **CK7 (+)** - Broad epithelial marker\n‚úÖ **PAS (+)** - Mucin production\n‚ùå **CK20 (‚àí)** - Rules out GI origin\n‚ùå **p40/p63 (‚àí)** - Rules out squamous\n\n**SQUAMOUS CELL CARCINOMA Profile:**\n\n‚ùå **TTF-1 (‚àí)** - Key difference!\n‚úÖ **p40/p63 (+)** - Most specific for squamous ‚≠ê\n‚úÖ **CK5/6 (+)** - Squamous marker\n‚úÖ **p16 (+/‚àí)** - Variable\n‚ùå **Napsin A (‚àí)** - Absent\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ CLINICAL SIGNIFICANCE:\n\n**TTF-1 is POSITIVE in:**\n\n**1. LUNG:**\n‚Ä¢ **Primary lung adenocarcinoma** (75-80%) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Small cell lung cancer** (85-90%)\n‚Ä¢ Expressed in type II pneumocytes\n\n**2. THYROID:**\n‚Ä¢ **Thyroid follicular cells** (normal and neoplastic)\n‚Ä¢ Papillary thyroid carcinoma\n‚Ä¢ Follicular thyroid carcinoma\n\n**Why this matters:**\n‚Üí Helps distinguish **PRIMARY lung adenocarcinoma** from metastases\n‚Üí **Metastatic adenocarcinoma** from breast, colon, pancreas are TTF-1 **NEGATIVE**\n‚Üí If lung mass is TTF-1+, likely **PRIMARY** lung cancer\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ DIFFERENTIAL DIAGNOSIS:\n\n**TTF-1 Positive Lung Mass:**\n‚Ä¢ Primary lung adenocarcinoma ‚≠ê\n‚Ä¢ Small cell lung cancer\n‚Ä¢ Metastatic thyroid cancer (rare)\n\n**TTF-1 Negative Lung Mass:**\n‚Ä¢ Squamous cell carcinoma\n‚Ä¢ Metastatic adenocarcinoma (breast, GI, etc.)\n‚Ä¢ Large cell carcinoma (mostly)\n‚Ä¢ Mesothelioma\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**TTF-1 = ADENOCARCINOMA OF LUNG** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**T**hyroid and **T**horacic (lung) **F**actor-**1**\"\n\n‚Ä¢ Most sensitive and specific marker for **primary lung adenocarcinoma**\n‚Ä¢ Helps differentiate **primary vs metastatic** disease\n‚Ä¢ **Nuclear staining** pattern (transcription factor)\n‚Ä¢ Combined with **Napsin A** for maximum specificity",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-6",
    subjectId: "pathology",
    chapterId: "neet-pg-2024",
    question: "10-year-old male presents with cervical lymphadenopathy, Surface Ig+, CD34-,\nCD5-, CD23-, Tdt-, CD10+, CD19+:",
    options: [
      "Burkitt‚Äôs Lymphoma",
      "Diffuse Large B-cell Lymphoma (DLBCL)",
      "Anaplastic Large Cell Lymphoma (ALCL)",
      "B-cell Acute Lymphoblastic Leukemia (B-ALL)"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Burkitt's Lymphoma (Option A)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Burkitt's Lymphoma** is a **highly aggressive B-cell non-Hodgkin lymphoma** with the **HIGHEST proliferation rate** (Ki-67 >95%) among all lymphomas.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå IMMUNOPHENOTYPING ANALYSIS:\n\n**GIVEN MARKERS:**\n\n‚Ä¢ **Surface Ig (+)** ‚≠ê = MATURE B-cell\n‚Ä¢ **CD34 (‚àí)** ‚≠ê‚≠ê‚≠ê = NOT immature!\n‚Ä¢ **CD5 (‚àí)** = NOT CLL/MCL\n‚Ä¢ **CD23 (‚àí)** = NOT CLL\n‚Ä¢ **TdT (‚àí)** ‚≠ê‚≠ê‚≠ê = NOT lymphoblastic!\n‚Ä¢ **CD10 (+)** ‚≠ê = Germinal center origin\n‚Ä¢ **CD19 (+)** ‚≠ê = B-cell marker\n\n**This = MATURE B-CELL LYMPHOMA** üéØ\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ BURKITT'S LYMPHOMA PROFILE:\n\n**POSITIVE MARKERS:**\n\n‚úÖ **Surface Ig (+)** ‚Üí **MATURE B-cell** (NOT precursor) ‚≠ê‚≠ê‚≠ê\n\n‚úÖ **CD10 (+)** ‚Üí **Germinal center** origin (CALLA antigen)\n\n‚úÖ **CD19 (+), CD20 (+)** ‚Üí Pan B-cell markers\n\n‚úÖ **Ki-67 >95%** ‚Üí **EXTREMELY HIGH proliferation!** ‚≠ê‚≠ê‚≠ê\n\n‚úÖ **BCL-6 (+)** ‚Üí Germinal center marker\n\n**NEGATIVE MARKERS:**\n\n‚ùå **CD34 (‚àí)** ‚Üí **NOT immature/precursor** ‚≠ê‚≠ê‚≠ê\n\n‚ùå **TdT (‚àí)** ‚Üí **NOT lymphoblastic** ‚≠ê‚≠ê‚≠ê\n\n‚ùå **CD5 (‚àí), CD23 (‚àí)** ‚Üí Rules out CLL, MCL\n\n‚ùå **BCL-2 (‚àí)** ‚Üí Unlike follicular lymphoma\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ DIFFERENTIAL DIAGNOSIS:\n\n**1. BURKITT'S LYMPHOMA** ‚≠ê‚≠ê‚≠ê (CORRECT)\n‚Ä¢ Surface Ig **(+)** - Mature\n‚Ä¢ CD34 **(‚àí)** - Not immature\n‚Ä¢ TdT **(‚àí)** - Not lymphoblastic\n‚Ä¢ **Ki-67 >95%** - Fastest growing!\n‚Ä¢ Age: 10 years old ‚úì\n\n**2. B-ALL (B-cell Acute Lymphoblastic Leukemia)** ‚ùå\n‚Ä¢ Surface Ig **(‚àí)** - Immature ‚ö†Ô∏è\n‚Ä¢ CD34 **(+)** - Precursor marker ‚ö†Ô∏è\n‚Ä¢ TdT **(+)** - Lymphoblastic ‚ö†Ô∏è\n‚Ä¢ Represents **IMMATURE** B-cells\n\n**3. DLBCL** ‚ùå\n‚Ä¢ Similar markers but **Ki-67 60-80%** (lower)\n‚Ä¢ Older age group\n\n**4. ALCL** ‚ùå\n‚Ä¢ **CD30 (+)**, CD19/CD20 **(‚àí)**\n‚Ä¢ T-cell origin\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüß¨ MOLECULAR & HISTOLOGY:\n\n**CYTOGENETICS:**\n\n‚Ä¢ **t(8;14)** - **MYC translocation** (80%) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ t(2;8) or t(8;22) variants (20%)\n‚Ä¢ **MYC gene** (chr 8) ‚Üí **IgH** (chr 14)\n‚Ä¢ ‚Üí **MYC overexpression** ‚Üí uncontrolled proliferation\n\n**HISTOLOGY:**\n\n‚Ä¢ **\"Starry sky\" appearance** ‚≠ê‚≠ê‚≠ê\n  ‚Üí \"Sky\" = densely packed lymphoma cells\n  ‚Üí \"Stars\" = tingible body macrophages\n  ‚Üí Macrophages eating apoptotic tumor cells\n‚Ä¢ Medium-sized cells, round nuclei\n‚Ä¢ Basophilic cytoplasm\n‚Ä¢ High mitotic rate\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüåç CLINICAL TYPES:\n\n**1. ENDEMIC (African)**\n‚Ä¢ **EBV positive** (>95%) ‚≠ê\n‚Ä¢ **Jaw/facial bones** involvement\n‚Ä¢ Age: 4-7 years\n‚Ä¢ Malaria belt association\n\n**2. SPORADIC (Western)**\n‚Ä¢ **EBV positive** (15-20%)\n‚Ä¢ **Abdomen** (ileocecal) ‚≠ê\n‚Ä¢ Presents as abdominal mass\n\n**3. IMMUNODEFICIENCY**\n‚Ä¢ HIV/AIDS, post-transplant\n‚Ä¢ **EBV positive** (25-40%)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ö° CLINICAL FEATURES:\n\n‚Ä¢ **Rapidly growing mass** (doubling: 24-48 hrs!)\n‚Ä¢ **B symptoms** (fever, night sweats, weight loss)\n‚Ä¢ **Cervical lymphadenopathy** (as in this case)\n‚Ä¢ **CNS involvement** (25%)\n‚Ä¢ **Tumor lysis syndrome** risk ‚ö†Ô∏è\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**\"BURKITT'S = MATURE, NOT A BABY!\"** ‚≠ê‚≠ê‚≠ê\n\n‚Ä¢ Surface Ig **(+)** = Mature\n‚Ä¢ CD34 **(‚àí)** = NOT immature\n‚Ä¢ TdT **(‚àí)** = NOT lymphoblastic\n‚Ä¢ **Ki-67 >95%** = Fastest lymphoma!\n‚Ä¢ **t(8;14) MYC** = Hallmark\n‚Ä¢ **\"Starry sky\"** = Diagnostic",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-7",
    subjectId: "pathology",
    chapterId: "neet-pg-2024",
    question: "Most common mutation in Papillary cell carcinoma?",
    options: [
      "BRAF V600E",
      "RET",
      "MET",
      "RAS"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **BRAF V600E (Option A)**\n\nüî¨ DETAILED EXPLANATION:\n\n**BRAF V600E** is the **MOST COMMON genetic mutation** in **Papillary Thyroid Carcinoma (PTC)**, occurring in **40-45%** of cases.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå THYROID CANCER MUTATIONS:\n\n**PAPILLARY THYROID CARCINOMA (PTC):** ‚≠ê\n\n‚Ä¢ **BRAF V600E: 40-45%** ‚≠ê‚≠ê‚≠ê (MOST COMMON - ANSWER!)\n‚Ä¢ **RET/PTC rearrangement: 20-30%** (radiation-induced, children)\n‚Ä¢ **RAS mutation: 10-15%** (follicular variant PTC)\n‚Ä¢ **NTRK fusion: 5-10%** (pediatric)\n\n**FOLLICULAR THYROID CARCINOMA (FTC):**\n\n‚Ä¢ **RAS mutation: 40-50%**\n‚Ä¢ **PAX8/PPARŒ≥ rearrangement: 30-40%**\n\n**MEDULLARY THYROID CARCINOMA (MTC):**\n\n‚Ä¢ **RET mutation: 98%** (hereditary MEN 2)\n\n**ANAPLASTIC THYROID CARCINOMA (ATC):**\n\n‚Ä¢ **p53 mutation** + BRAF/RAS (often evolves from PTC/FTC)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüß¨ MAPK/ERK SIGNALING PATHWAY:\n\n**NORMAL CELL:**\n\nGrowth Factor ‚Üí Receptor ‚Üí RAS ‚Üí **RAF (BRAF)** ‚Üí MEK ‚Üí ERK\n                                     ‚Üì\n                        Controlled Cell Growth ‚úì\n\n**BRAF V600E MUTATION:**\n\n‚úó **No Growth Factor needed!**\n         ‚Üì\n**BRAF V600E (CONSTITUTIVELY ACTIVE!)** ‚ö°‚ö°‚ö°\n         ‚Üì\n**MEK** ‚Üë‚Üë‚Üë (Hyperactivated)\n         ‚Üì\n**ERK** ‚Üë‚Üë‚Üë (Hyperactivated)\n         ‚Üì\n**Uncontrolled Cell Proliferation** ‚Üí **CANCER!**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ CLINICAL SIGNIFICANCE OF BRAF V600E:\n\n**WORSE PROGNOSIS INDICATORS:** ‚ö†Ô∏è\n\n‚Ä¢ **More aggressive tumor behavior**\n‚Ä¢ **Higher recurrence rate** (2-3x increased)\n‚Ä¢ **Increased lymph node metastasis**\n‚Ä¢ **Extrathyroidal extension** (invades surrounding tissues)\n‚Ä¢ **Higher stage at presentation**\n‚Ä¢ **Radioiodine resistance** (‚Üì NIS expression)\n‚Ä¢ **Worse disease-free survival**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä THERAPEUTIC IMPLICATIONS:\n\n**TARGETED THERAPY:**\n\n‚Ä¢ **Vemurafenib** - BRAF V600E inhibitor ‚≠ê\n‚Ä¢ **Dabrafenib** - BRAF inhibitor\n‚Ä¢ **Trametinib** - MEK inhibitor (combination therapy)\n\n**Used for:**\n‚Ä¢ **Advanced/metastatic PTC**\n‚Ä¢ **Radioiodine-refractory disease**\n‚Ä¢ **Anaplastic thyroid cancer** with BRAF mutation\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüîç WHY OTHER OPTIONS ARE WRONG:\n\n‚ùå **RET:**\n‚Ä¢ **2nd most common** in PTC (20-30%)\n‚Ä¢ More common in **radiation-induced** PTC\n‚Ä¢ **Hallmark** of **Medullary thyroid cancer** (98%)\n\n‚ùå **MET:**\n‚Ä¢ Less common in PTC\n‚Ä¢ More associated with **follicular-patterned** tumors\n\n‚ùå **RAS:**\n‚Ä¢ **3rd most common** in PTC (10-15%)\n‚Ä¢ More common in **Follicular thyroid carcinoma** (40-50%)\n‚Ä¢ Associated with **follicular variant PTC**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìã PAPILLARY THYROID CARCINOMA FEATURES:\n\n**HISTOLOGY:**\n‚Ä¢ **Orphan Annie eye** nuclei (ground glass)\n‚Ä¢ **Psammoma bodies** (calcifications)\n‚Ä¢ **Nuclear grooves**\n‚Ä¢ **Papillary architecture**\n\n**CLINICAL:**\n‚Ä¢ **Most common** thyroid cancer (80-85%)\n‚Ä¢ **Best prognosis** overall\n‚Ä¢ **Lymph node spread** common (40%)\n‚Ä¢ **Excellent survival** (>95% at 10 years)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**BRAF V600E = MOST COMMON PTC MUTATION** ‚≠ê‚≠ê‚≠ê\n\n**Remember: \"BRAF = Bad, Risky, Aggressive, Fast PTC!\"**\n\n‚Ä¢ **40-45%** of all PTC\n‚Ä¢ **V600E** = Valine ‚Üí Glutamic acid at position 600\n‚Ä¢ **Constitutively active** MAPK pathway\n‚Ä¢ **Worse prognosis** but **targetable** with Vemurafenib\n‚Ä¢ **Always think BRAF** in aggressive PTC!",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-10",
    subjectId: "pathology",
    chapterId: "neet-pg-2024",
    question: "Young male died during exercise. History of similar deaths in sibling, On gross\nmorphology: septal thickening was seen. Most common cause of death?",
    options: [
      "Dilated Cardiomyopathy (DCM)",
      "Restrictive Cardiomyopathy (RCM)",
      "Hypertrophic Obstructive Cardiomyopathy (HOCM)",
      "Viral Myocarditis"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Hypertrophic Obstructive Cardiomyopathy (HOCM) - Option C**\n\nüî¨ DETAILED EXPLANATION:\n\n**HOCM** is the **#1 CAUSE** of **sudden cardiac death in YOUNG ATHLETES** and individuals <35 years old. The case describes classic findings: **young male**, **sudden death during exercise**, **family history**, and **septal thickening** on gross morphology.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå CARDIOMYOPATHY COMPARISON:\n\n**‚òÖ HOCM (HCM)** ‚≠ê‚≠ê‚≠ê **(ANSWER!)**\n\n‚Ä¢ **Septum:** ‚Üë‚Üë‚Üë **THICK** (>15mm) - **Asymmetric Septal Hypertrophy (ASH)**\n‚Ä¢ **EF:** ‚Üë or Normal **(>60-70%)** - Hyperdynamic!\n‚Ä¢ **LV Cavity:** ‚Üì **SMALL** (\"Banana-shaped\")\n‚Ä¢ **LV Wall:** Thick\n‚Ä¢ **Genetics:** **Autosomal Dominant** (MYH7, MYBPC3)\n‚Ä¢ **Key finding:** **LVOT obstruction**\n\n**‚Ä¢ DCM (Dilated Cardiomyopathy)** ‚ùå\n\n‚Ä¢ Septum: Normal thickness\n‚Ä¢ EF: ‚Üì‚Üì **<40%** (systolic dysfunction)\n‚Ä¢ LV Cavity: ‚Üë‚Üë **LARGE** (dilated)\n‚Ä¢ Causes: Alcohol, viral, idiopathic\n‚Ä¢ Presents with **heart failure** (not sudden death)\n\n**‚Ä¢ RCM (Restrictive Cardiomyopathy)** ‚ùå\n\n‚Ä¢ Septum: Normal\n‚Ä¢ EF: Normal\n‚Ä¢ LV Cavity: Normal size but **RIGID** (stiff)\n‚Ä¢ **Diastolic dysfunction** (filling problem)\n‚Ä¢ Rare; causes: Amyloidosis, sarcoidosis\n\n**‚Ä¢ Viral Myocarditis** ‚ùå\n\n‚Ä¢ **Acute inflammation** of myocardium\n‚Ä¢ Can cause sudden death but **NO familial pattern**\n‚Ä¢ **NO septal thickening** on gross exam\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nü´Ä PATHOPHYSIOLOGY:\n\n**HOCM Heart Anatomy:**\n\n‚Ä¢ **Asymmetric Septal Hypertrophy (ASH)** ‚≠ê‚≠ê‚≠ê\n  ‚Üí Septum >15mm (normal: 7-11mm)\n  ‚Üí **Interventricular septum** >> LV free wall\n  ‚Üí Creates **\"Banana-shaped\" LV cavity**\n\n‚Ä¢ **LVOT Obstruction** (Left Ventricular Outflow Tract)\n  ‚Üí Thick septum **narrows** outflow path\n  ‚Üí Blood has difficulty exiting LV\n\n‚Ä¢ **SAM (Systolic Anterior Motion)** ‚≠ê\n  ‚Üí Mitral valve **sucked forward** by Venturi effect\n  ‚Üí Worsens LVOT obstruction\n  ‚Üí Causes mitral regurgitation\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ö° SUDDEN DEATH MECHANISM:\n\n**Normal State:**\n‚Ä¢ Some LVOT obstruction at rest\n‚Ä¢ Can be asymptomatic\n\n**During EXERCISE:** ‚ö†Ô∏è\n\n**1. Increased Contractility**\n   ‚Üí Septum contracts harder\n   ‚Üì\n\n**2. Decreased LV Volume**\n   ‚Üí Less blood in chamber\n   ‚Üì\n\n**3. WORSE LVOT Obstruction**\n   ‚Üí Outflow path even narrower!\n   ‚Üì\n\n**4. Decreased Cardiac Output**\n   ‚Üí Brain hypoperfusion\n   ‚Üì\n\n**5. Ventricular Arrhythmias**\n   ‚Üí **VT/VF** (myocardial disarray creates substrate)\n   ‚Üì\n\n**SUDDEN CARDIAC DEATH** ‚ö°‚ö°‚ö°\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ CLINICAL FEATURES:\n\n**TRIAD:**\n\n1. **Family history** of sudden death (AD inheritance)\n2. **Syncope with exercise** (LVOT obstruction worsens)\n3. **Systolic murmur** that ‚Üë with Valsalva\n\n**SYMPTOMS:**\n\n‚Ä¢ **Dyspnea** (exertional)\n‚Ä¢ **Angina** (despite normal coronaries - supply-demand mismatch)\n‚Ä¢ **Palpitations**\n‚Ä¢ **Syncope** (especially with exercise)\n‚Ä¢ **Sudden cardiac death** (often FIRST presentation!) ‚ö†Ô∏è\n\n**PHYSICAL EXAM:**\n\n‚Ä¢ **Harsh systolic murmur** at LLSB\n‚Ä¢ **‚Üë with Valsalva, standing** (‚Üì preload ‚Üí ‚Üë obstruction)\n‚Ä¢ **‚Üì with squatting, handgrip** (‚Üë afterload ‚Üí ‚Üì obstruction)\n‚Ä¢ **Double apical impulse** (presystolic impulse)\n‚Ä¢ **Jerky carotid pulse** (\"spike and dome\")\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ HISTOPATHOLOGY:\n\n‚Ä¢ **Myocardial disarray** ‚≠ê‚≠ê‚≠ê (Hallmark!)\n  ‚Üí Disorganized myocyte arrangement\n  ‚Üí Creates arrhythmia substrate\n\n‚Ä¢ **Myocyte hypertrophy**\n‚Ä¢ **Interstitial fibrosis**\n‚Ä¢ **Thickened intramural coronaries**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüîç DIAGNOSIS:\n\n**ECHO (Gold Standard):**\n‚Ä¢ **Septal thickness >15mm** (or >13mm with family history)\n‚Ä¢ **SAM of mitral valve**\n‚Ä¢ **LVOT gradient** >30 mmHg\n‚Ä¢ Small LV cavity\n\n**ECG:**\n‚Ä¢ **LVH** with strain\n‚Ä¢ **Deep Q waves** (septal)\n‚Ä¢ **T wave inversion**\n\n**Genetic Testing:**\n‚Ä¢ **MYH7** (Œ≤-myosin heavy chain) - 40%\n‚Ä¢ **MYBPC3** (myosin-binding protein C) - 40%\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT:\n\n**AVOID:**\n‚Ä¢ **Competitive sports** ‚ö†Ô∏è\n‚Ä¢ **Dehydration**\n‚Ä¢ **Vasodilators** (nitroglycerin - worsens obstruction!)\n‚Ä¢ **Digoxin** (‚Üë contractility ‚Üí worse)\n\n**MEDICATIONS:**\n‚Ä¢ **Beta-blockers** (metoprolol) - 1st line ‚≠ê\n‚Ä¢ **Calcium channel blockers** (verapamil)\n‚Ä¢ **Disopyramide** (antiarrhythmic)\n\n**INTERVENTIONS:**\n‚Ä¢ **ICD** (Implantable Cardioverter-Defibrillator) - High-risk patients ‚≠ê\n‚Ä¢ **Septal myectomy** (surgery)\n‚Ä¢ **Alcohol septal ablation**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINTS FOR EXAM:\n\n**HOCM = #1 CAUSE OF SUDDEN DEATH IN YOUNG ATHLETES** ‚≠ê‚≠ê‚≠ê\n\n**Remember: \"HOCM Hits Obstructing Cardiac Marathon runners\"**\n\n‚Ä¢ **Asymmetric Septal Hypertrophy** (>15mm)\n‚Ä¢ **Autosomal Dominant** (MYH7, MYBPC3)\n‚Ä¢ **Worse with exercise** (‚Üë obstruction)\n‚Ä¢ **Myocardial disarray** = arrhythmia substrate\n‚Ä¢ **SAM** = Systolic Anterior Motion\n‚Ä¢ Murmur **‚Üë with Valsalva/standing**\n‚Ä¢ **Beta-blockers** = Treatment\n‚Ä¢ **ICD** for high-risk patients",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-26",
    subjectId: "pathology",
    chapterId: "neet-pg-2024",
    question: "Diagnosis of MRCP image:",
    options: [
      "GB Stone (Gallbladder Stone)",
      "Cholangiocarcinoma",
      "Choledochal Cyst",
      "Gall and Blood Cancer"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Cholangiocarcinoma (Option B)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Cholangiocarcinoma (CCA)** is a **malignant tumor** arising from **bile duct epithelium**, presenting as a **stricture or mass** on MRCP imaging.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå CLASSIFICATION BY LOCATION:\n\n**INTRAHEPATIC CCA** (10-20%)\n‚Ä¢ Within liver parenchyma\n‚Ä¢ Mass lesion\n‚Ä¢ Better prognosis\n\n**PERIHILAR (Klatskin tumor)** ‚≠ê‚≠ê‚≠ê (50-60%) **MOST COMMON**\n‚Ä¢ **Confluence of right & left hepatic ducts**\n‚Ä¢ **Stricture** appearance on MRCP ‚≠ê\n‚Ä¢ Worst prognosis\n‚Ä¢ Named after Gerald Klatskin\n\n**DISTAL (Extrahepatic)** (20-30%)\n‚Ä¢ Common bile duct\n‚Ä¢ Presents like pancreatic head cancer\n‚Ä¢ Jaundice early\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ MRCP FINDINGS:\n\n**CHOLANGIOCARCINOMA:**\n‚Ä¢ **Irregular stricture** ‚≠ê‚≠ê‚≠ê (abrupt, asymmetric)\n‚Ä¢ **Bile duct cutoff** (sudden termination)\n‚Ä¢ **Upstream dilatation** (dilated ducts proximal to stricture)\n‚Ä¢ **Mass** (if intrahepatic)\n‚Ä¢ **\"Pruned tree\" appearance** (peripheral ducts not filling)\n‚Ä¢ May show **vascular encasement**\n\n**MRCP = Magnetic Resonance Cholangiopancreatography:**\n‚Ä¢ **Non-invasive** visualization of biliary tree\n‚Ä¢ **Gold standard** for biliary imaging ‚≠ê\n‚Ä¢ Shows anatomy without contrast\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ RISK FACTORS:\n\n**HIGH RISK:**\n‚Ä¢ **Primary Sclerosing Cholangitis (PSC)** ‚≠ê‚≠ê‚≠ê (10-15% lifetime risk)\n‚Ä¢ **Liver flukes** (*Clonorchis sinensis*, *Opisthorchis viverrini*) - Asia\n‚Ä¢ **Choledochal cysts**\n‚Ä¢ **Hepatolithiasis** (intrahepatic stones)\n‚Ä¢ **Thorotrast exposure** (old contrast agent)\n‚Ä¢ **Chronic hepatitis B/C**\n\n**ASSOCIATIONS:**\n‚Ä¢ **Ulcerative colitis** (via PSC)\n‚Ä¢ **Caroli disease**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE INCORRECT:\n\n**A. Gallbladder Stone** ‚ùå\n‚Ä¢ **Filling defect** in GB (not bile duct stricture)\n‚Ä¢ **Mobile** (changes position)\n‚Ä¢ **Round/oval** shape\n‚Ä¢ **Acoustic shadow** on ultrasound\n‚Ä¢ **No bile duct stricture** ‚ö†Ô∏è\n‚Ä¢ May cause **secondary** CBD obstruction but different appearance\n\n**C. Choledochal Cyst** ‚ùå\n‚Ä¢ **Congenital dilatation** of bile ducts ‚≠ê\n‚Ä¢ **Smooth, fusiform** dilatation (NOT stricture) ‚ö†Ô∏è\n‚Ä¢ **Todani classification** (Type I-V)\n‚Ä¢ MRCP shows **cystic dilatation**, not stricture\n‚Ä¢ Presents in **children** usually\n‚Ä¢ **Increased risk** of cholangiocarcinoma (10-15%)\n\n**D. Gall and Blood Cancer** ‚ùå\n‚Ä¢ Not a recognized medical term\n‚Ä¢ Possibly referring to **gallbladder carcinoma**?\n‚Ä¢ GB carcinoma:\n  ‚Üí **Thickened GB wall** (>3mm)\n  ‚Üí **Mass** replacing GB\n  ‚Üí **NOT bile duct stricture**\n  ‚Üí Different imaging appearance\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ CLINICAL PRESENTATION:\n\n**SYMPTOMS:**\n‚Ä¢ **Painless progressive jaundice** ‚≠ê‚≠ê‚≠ê (most common)\n‚Ä¢ **Pruritus** (itching from bile salts)\n‚Ä¢ **Weight loss** (malignancy)\n‚Ä¢ **Clay-colored stools** (acholic)\n‚Ä¢ **Dark urine** (tea-colored)\n‚Ä¢ **Hepatomegaly**\n‚Ä¢ **Courvoisier sign** (palpable, non-tender GB) - if distal\n\n**LABS:**\n‚Ä¢ **‚Üë‚Üë Alkaline phosphatase** ‚≠ê‚≠ê‚≠ê (cholestatic pattern)\n‚Ä¢ **‚Üë‚Üë Direct bilirubin** (conjugated)\n‚Ä¢ **‚Üë GGT**\n‚Ä¢ **CA 19-9** elevated (tumor marker, not specific)\n‚Ä¢ **CEA** may be elevated\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìã DIAGNOSTIC WORKUP:\n\n**IMAGING:**\n\n**1. MRCP** ‚≠ê‚≠ê‚≠ê **BEST non-invasive**\n‚Ä¢ Shows stricture, level of obstruction\n‚Ä¢ Assesses resectability\n\n**2. CT Abdomen with contrast**\n‚Ä¢ Staging (metastases, vascular involvement)\n‚Ä¢ Lymph nodes\n\n**3. ERCP** (Endoscopic Retrograde Cholangiopancreatography)\n‚Ä¢ **Diagnostic + therapeutic**\n‚Ä¢ Can obtain **brush cytology/biopsy**\n‚Ä¢ Can place **stent** for drainage\n\n**4. PET-CT** (staging)\n\n**BIOPSY:**\n‚Ä¢ Often **not needed** preoperatively if resectable\n‚Ä¢ Risk of **peritoneal seeding**\n‚Ä¢ ERCP brushings (low sensitivity ~30%)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT:\n\n**CURATIVE:**\n\n**SURGERY** (only curative option) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Resectable** in only 20-30% at diagnosis ‚ö†Ô∏è\n\n**Perihilar (Klatskin):**\n‚Ä¢ **Hepatic resection + bile duct excision**\n‚Ä¢ Very complex surgery\n‚Ä¢ 5-year survival: 20-40%\n\n**Distal:**\n‚Ä¢ **Whipple procedure** (pancreaticoduodenectomy)\n‚Ä¢ Better outcomes than perihilar\n\n**Intrahepatic:**\n‚Ä¢ **Hepatectomy** (liver resection)\n\n**PALLIATIVE:**\n\n**1. BILIARY DRAINAGE** ‚≠ê\n‚Ä¢ **ERCP with stenting** (plastic or metal)\n‚Ä¢ **Percutaneous transhepatic drainage (PTD)**\n‚Ä¢ Relieves jaundice, pruritus\n\n**2. CHEMOTHERAPY**\n‚Ä¢ **Gemcitabine + Cisplatin** (standard)\n‚Ä¢ Modest survival benefit\n\n**PROGNOSIS:**\n‚Ä¢ **Poor** overall (5-year survival <10% for unresectable)\n‚Ä¢ **Late diagnosis** (usually advanced at presentation)\n‚Ä¢ **Perihilar worst** prognosis\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**Cholangiocarcinoma on MRCP = Irregular stricture + Upstream dilatation** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**C**holangiocarcinoma **C**auses **C**utoff (stricture)!\"\n\n**Classic presentation:**\n‚Ä¢ **Painless progressive jaundice**\n‚Ä¢ **‚Üë‚Üë Alkaline phosphatase** (cholestatic)\n‚Ä¢ **MRCP:** Irregular bile duct stricture\n‚Ä¢ **Most common site:** Perihilar (Klatskin tumor)\n\n**Risk factors:** **PSC** (primary sclerosing cholangitis) ‚≠ê‚≠ê‚≠ê\n\n**Treatment:** Surgery only if resectable (minority), otherwise palliative drainage + chemo",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-70",
    subjectId: "pathology",
    chapterId: "neet-pg-2024",
    question: "A diaphyseal tumor, probably small round blue cells. Which test/translocation is\nuseful for diagnosis?",
    options: [
      "t(11;22)",
      "t(15;17)",
      "t(8;14)",
      "t(9;22)"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **t(11;22) (Option A)**\n\nüî¨ **EWING'S SARCOMA:**\n\n**CLASSIC FEATURES:**\n‚Ä¢ **\"Small round blue cell tumor\"** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Diaphysis** (shaft) of long bones ‚≠ê‚≠ê‚≠ê **(vs Osteosarcoma = metaphysis)**\n‚Ä¢ **Children/adolescents** (5-15 years)\n‚Ä¢ **2nd most common** bone malignancy (after osteosarcoma)\n\n**TRANSLOCATION:** **t(11;22)(q24;q12)** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **EWS-FLI1** fusion gene (85%)\n‚Ä¢ **EWS gene** (chr 22) fuses with **FLI1** (chr 11)\n‚Ä¢ **Diagnostic** (confirms Ewing's) ‚≠ê\n‚Ä¢ Detected by **FISH** or **RT-PCR**\n\n**LOCATION:**\n‚Ä¢ **Femur, tibia, humerus** (diaphysis)\n‚Ä¢ **Pelvis, ribs** (flat bones)\n\n**RADIOGRAPHIC:**\n‚Ä¢ **\"Onion peel\" periosteal reaction** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Permeative** lytic lesion\n‚Ä¢ **Soft tissue mass**\n\n**OTHER TRANSLOCATIONS:**\n‚Ä¢ **t(15;17):** **APL** (Acute Promyelocytic Leukemia) ‚ö†Ô∏è\n‚Ä¢ **t(8;14):** **Burkitt's lymphoma** ‚ö†Ô∏è\n‚Ä¢ **t(9;22):** **CML** (Philadelphia chromosome) ‚ö†Ô∏è\n\n**TREATMENT:**\n‚Ä¢ **Neoadjuvant chemotherapy** + **Surgery/RT**\n\nüí° **KEY:** **Diaphyseal + Small round blue cells = Ewing's ‚Üí t(11;22)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2023-177",
    subjectId: "pathology",
    chapterId: "neet-pg-2023",
    question: "Which of the following is true regarding the Mendelian mode of inheritance?",
    options: [
      "Every 10th patient has a Y-linked disorder",
      "1/3rd of Mendelian disorders is autosomal recessive",
      "Every 5th patient has an X-linked recessive disorder",
      "2/3 r d of Mendelian disorders are autosomal dominant",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **2/3 of Mendelian disorders are autosomal dominant (Option D)**\n\nüî¨ **MENDELIAN DISORDERS - DISTRIBUTION:**\n\n**AUTOSOMAL DOMINANT:** ‚≠ê‚≠ê‚≠ê **~65-75%** (roughly 2/3) ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Examples:** Huntington's, Marfan, Achondroplasia, ADPKD\n‚Ä¢ **Vertical transmission**\n‚Ä¢ **50% offspring risk**\n\n**AUTOSOMAL RECESSIVE:** **~20-25%**\n‚Ä¢ **Examples:** Sickle cell, CF, Thalassemia, PKU\n‚Ä¢ **Horizontal transmission**\n‚Ä¢ **25% offspring risk** (if both carriers)\n\n**X-LINKED:** **~5-10%**\n‚Ä¢ **Examples:** Hemophilia A/B, Duchenne MD, G6PD deficiency\n‚Ä¢ **Mostly males affected**\n\n**Y-LINKED:** **<1%** (VERY rare)\n‚Ä¢ **Male infertility genes**\n‚Ä¢ **Only males affected**\n\n**WHY AD MOST COMMON:**\n‚Ä¢ **Manifests in heterozygotes** (one mutant allele sufficient)\n‚Ä¢ **Better reproductive fitness** than AR\n‚Ä¢ **Not lethal** (usually)\n\n**IMPORTANT:**\n‚Ä¢ **Most common inheritance:** **Autosomal dominant** ‚≠ê‚≠ê‚≠ê\n\nüí° **KEY:** **~2/3 of Mendelian disorders are Autosomal Dominant** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-182",
    subjectId: "pathology",
    chapterId: "neet-pg-2023",
    question: "r A child presents with intermittent jaundice and splenomegaly. There is a history of similar e complaints in the elder brother. Peripheral smear shows the following finding. How will you investigate this condition? d d a L p e",
    options: [
      "Osmotic frargility test - Hereditary spherocytosis",
      "P Coombs test - AIHA",
      "G6PD deficiency - Genetic testing",
      "Paroxysmal nocturnal hemoglobinuria - Flow cytometry",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Osmotic fragility test - Hereditary spherocytosis (Option A)**\n\nüî¨ **HEREDITARY SPHEROCYTOSIS (HS):**\n\n**THIS CASE:**\n‚Ä¢ **Intermittent jaundice** ‚≠ê\n‚Ä¢ **Splenomegaly** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Family history** (elder brother) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Peripheral smear:** Spherocytes ‚≠ê‚≠ê‚≠ê\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **Spectrin/ankyrin deficiency** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Membrane defect** ‚Üí Loss of membrane\n‚Ä¢ **Sphere-shaped RBCs** (lose biconcave shape)\n‚Ä¢ **Trapped in spleen** ‚Üí **Hemolysis**\n\n**INHERITANCE:** **Autosomal dominant** ‚≠ê (75%)\n\n**CLINICAL:**\n‚Ä¢ **Hemolytic anemia** ‚≠ê\n‚Ä¢ **Jaundice** (unconjugated)\n‚Ä¢ **Splenomegaly** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Gallstones** (pigment stones)\n\n**DIAGNOSTIC TEST:** **OSMOTIC FRAGILITY TEST** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Spherocytes** lyse easily in hypotonic saline\n‚Ä¢ **Increased fragility** ‚≠ê‚≠ê‚≠ê\n\n**TREATMENT:**\n‚Ä¢ **Splenectomy** ‚≠ê‚≠ê‚≠ê (curative)\n‚Ä¢ **Folic acid** supplementation\n\nüí° **KEY:** **Spherocytes + Family history + Splenomegaly = HS ‚Üí Osmotic fragility test** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page90_img46.jpeg",
    year: 2023
  },{
    id: "neet-pg-2023-1",
    subjectId: "pathology",
    chapterId: "neet-pg-2023",
    question: "An African child is found to have a mass in the jaw. A biopsy of the mass was done, and it appears as shown in the image below. The child also had a translocation of t(8;14). What is the probable diagnosis? r e d",
    options: [
      "Acute myeloid leukemia",
      "Follicular lymphoma a",
      "Multiple myeloma",
      "Burkitt lymphoma",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Burkitt lymphoma (Option D)**\n\nüî¨ **BURKITT LYMPHOMA:**\n\n**THIS CASE - CLASSIC:**\n‚Ä¢ **African child** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Jaw mass** ‚≠ê‚≠ê‚≠ê (most common presentation in Africa)\n‚Ä¢ **t(8;14) translocation** ‚≠ê‚≠ê‚≠ê **(PATHOGNOMONIC)**\n‚Ä¢ **Biopsy:** (From image) Starry sky appearance\n\n**GENETICS:**\n‚Ä¢ **t(8;14)** translocation ‚≠ê‚≠ê‚≠ê (80%)\n  - **c-MYC** oncogene (chromosome 8) moves to IGH (chromosome 14)\n  - Also: t(2;8), t(8;22)\n‚Ä¢ **EBV association** (African/endemic type) ‚≠ê\n\n**TYPES:**\n‚Ä¢ **Endemic** (African) ‚≠ê - Jaw/facial bones, EBV+\n‚Ä¢ **Sporadic** (Western) - Abdomen (ileocecal)\n‚Ä¢ **Immunodeficiency-related** (HIV)\n\n**HISTOLOGY:** **STARRY SKY** appearance ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Sheets of lymphocytes** (dark sky)\n‚Ä¢ **Scattered macrophages** (stars) eating apoptotic cells\n\n**CLINICAL:**\n‚Ä¢ **Rapidly growing** mass\n‚Ä¢ **Children/young adults**\n\n**TREATMENT:**\n‚Ä¢ **Intensive chemotherapy** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **High cure rate** (>80%)\n\nüí° **KEY:** **African child + Jaw mass + t(8;14) + Starry sky = Burkitt lymphoma** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-188",
    subjectId: "pathology",
    chapterId: "neet-pg-2023",
    question: "A child presented to the hospital Lwith cola-colored urine, hypertension, and puffiness of eyes. Laboratory investigations were done, and creatinine was 2.5 mg/dL. Treatment was started, and despite treatment, the patient did not improve for the next 3 weeks. The creatinine vaplue increased to 4.5 mg/dL. Which among the following electron microscopic findings will be seen in this patient?",
    options: [
      "Subendothelial deeposits",
      "Subepithelial deposits r",
      "Crescent formation P",
      "Mesangial deposits",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Subepithelial deposits (Option B)**\n\nüî¨ **POST-STREPTOCOCCAL GLOMERULONEPHRITIS (PSGN):**\n\n**THIS CASE:**\n‚Ä¢ **Cola-colored urine** (hematuria) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Hypertension** ‚≠ê\n‚Ä¢ **Puffiness** (periorbital edema) ‚≠ê\n‚Ä¢ **‚Üë Creatinine** (2.5 ‚Üí 4.5 mg/dL) ‚≠ê\n‚Ä¢ **Not improving** after 3 weeks ‚≠ê\n\n**ACUTE GLOMERULONEPHRITIS** ‚≠ê‚≠ê‚≠ê\n\n**PSGN - ELECTRON MICROSCOPY:**\n‚Ä¢ **SUBEPITHELIAL deposits** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Immune complexes** on epithelial side of GBM\n‚Ä¢ **\"Humps\" on EM** ‚≠ê‚≠ê‚≠ê\n\n**LIGHT MICROSCOPY:**\n‚Ä¢ **Diffuse proliferative** GN\n‚Ä¢ **Hypercellular glomeruli**\n\n**IMMUNOFLUORESCENCE:**\n‚Ä¢ **Starry sky** pattern (granular)\n‚Ä¢ **IgG, C3 deposits**\n\n**CLINICAL:**\n‚Ä¢ **2-3 weeks** post-streptococcal infection\n‚Ä¢ **Children** (6-10 years)\n‚Ä¢ **Self-limited** (usually)\n\n**OTHER PATTERNS:**\n‚Ä¢ **Subendothelial:** SLE, MPGN\n‚Ä¢ **Mesangial:** IgA nephropathy\n‚Ä¢ **Crescents:** RPGN (rapidly progressive)\n\nüí° **KEY:** **Post-strep GN ‚Üí Subepithelial humps on EM** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-191",
    subjectId: "pathology",
    chapterId: "neet-pg-2023",
    question: "S ub-Topic: A patient was transfused 4 units of blood 2 hours ago, and now she complains of chest discomfort. X-ray shows bilateral fissural thickening. Which of the following is the most probable cause?",
    options: [
      "ABO incompatibility reactions",
      "Fluid overload",
      "Hypocalcemia",
      "Graft-versus-host disease",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Fluid overload (TACO - Transfusion Associated Circulatory Overload) (Option B)**\n\nüî¨ **TRANSFUSION-ASSOCIATED CIRCULATORY OVERLOAD (TACO):**\n\n**THIS CASE:**\n‚Ä¢ **4 units blood transfused** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **2 hours ago** ‚≠ê\n‚Ä¢ **Chest discomfort** ‚≠ê\n‚Ä¢ **CXR:** **Bilateral fissural thickening** ‚≠ê‚≠ê‚≠ê (fluid in fissures = pulmonary edema)\n\n**TACO:** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Volume overload** from rapid transfusion ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Most common** transfusion complication\n\n**CLINICAL:**\n‚Ä¢ **Dyspnea**, **tachypnea**\n‚Ä¢ **Chest tightness**\n‚Ä¢ **Hypertension** ‚≠ê (vs hypotension in TRALI)\n‚Ä¢ **‚Üë JVP**\n‚Ä¢ **Crackles** on auscultation\n\n**CXR:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Bilateral infiltrates**\n‚Ä¢ **Fissural thickening** ‚≠ê (fluid in fissures)\n‚Ä¢ **Cardiomegaly** (if pre-existing heart disease)\n\n**MANAGEMENT:**\n‚Ä¢ **Stop transfusion**\n‚Ä¢ **Sit upright**\n‚Ä¢ **Diuretics** (furosemide) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Oxygen**\n\n**VS TRALI:**\n‚Ä¢ **TRALI:** **Hypotension**, no cardiomegaly, antibody-mediated\n\nüí° **KEY:** **Multiple units + Chest discomfort + Fissural thickening = TACO (fluid overload)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-193",
    subjectId: "pathology",
    chapterId: "neet-pg-2023",
    question: "Question 193 - [Content needs manual review]",
    options: [
      "Option 1",
      "Option 2",
      "FSGS",
      "PSGN-associated disease",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Option 2**\n\nüî¨ Detailed explanation to be added.",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-194",
    subjectId: "pathology",
    chapterId: "neet-pg-2023",
    question: "A 5-year-old child is brought with fever, fatigue, and left ventricular dysfunction. An endomyocardial biopsy is shown below. What is the probable diagnosis? r e d d",
    options: [
      "Acute rheumatic fever",
      "Chagas disease",
      "Pyogenic myocarditis L",
      "Lymphocytic myocarditis",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Lymphocytic myocarditis (Viral myocarditis) (Option D)**\n\nüî¨ **LYMPHOCYTIC MYOCARDITIS:**\n\n**THIS CASE:**\n‚Ä¢ **5-year-old child** ‚≠ê\n‚Ä¢ **Fever** ‚≠ê\n‚Ä¢ **Fatigue**\n‚Ä¢ **LV dysfunction** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Biopsy:** (From image) Lymphocytic infiltration\n\n**CAUSE:** **Viral** (most common) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Coxsackie B virus** ‚≠ê‚≠ê‚≠ê (most common)\n‚Ä¢ **Adenovirus**, **Parvovirus B19**\n‚Ä¢ **HIV**, **HCV**\n\n**HISTOLOGY:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Lymphocytic infiltrate** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Myocyte necrosis**\n‚Ä¢ **NO eosinophils** (vs hypersensitivity)\n‚Ä¢ **NO giant cells** (vs giant cell myocarditis)\n\n**CLINICAL:**\n‚Ä¢ **Post-viral illness** (1-2 weeks after URTI)\n‚Ä¢ **Heart failure** symptoms\n‚Ä¢ **Arrhythmias**\n‚Ä¢ **Chest pain**\n\n**DIAGNOSIS:**\n‚Ä¢ **Endomyocardial biopsy** ‚≠ê‚≠ê‚≠ê (GOLD STANDARD)\n‚Ä¢ **‚Üë Troponin**\n‚Ä¢ **ECG:** ST changes\n\n**TREATMENT:**\n‚Ä¢ **Supportive** (heart failure management) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Immunosuppression** (if fulminant)\n\nüí° **KEY:** **Child + LV dysfunction + Lymphocytic infiltrate = Viral myocarditis** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page96_img50.jpeg",
    year: 2023
  },{
    id: "neet-pg-2023-195",
    subjectId: "pathology",
    chapterId: "neet-pg-2023",
    question: "r An elderly male is known as a smoker presented with chronic cough, significant weight loss, P and fatigue. Serum calcium level is raised. A lung biopsy was done, and it showed large atypical cells with hyperchromasia. What is the probable diagnosis?",
    options: [
      "Large cell neuroendocrine tumor",
      "Small cell carcinoma",
      "Adenocarcinoma",
      "Squamous cell carcinoma",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Squamous cell carcinoma (Option D)**\n\nüî¨ **LUNG SQUAMOUS CELL CARCINOMA (SCC):**\n\n**THIS CASE:**\n‚Ä¢ **Elderly male smoker** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Chronic cough** ‚≠ê\n‚Ä¢ **Weight loss**, **fatigue**\n‚Ä¢ **‚Üë Serum calcium** ‚≠ê‚≠ê‚≠ê **(HYPERCALCEMIA)**\n‚Ä¢ **Biopsy:** Large atypical cells with hyperchromasia\n\n**SCC & HYPERCALCEMIA:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Paraneoplastic** syndrome\n‚Ä¢ **PTH-rP** (Parathyroid hormone-related peptide) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Squamous cell** produces PTH-rP\n\n**HISTOLOGY:**\n‚Ä¢ **Keratin pearls** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Intercellular bridges**\n‚Ä¢ **Large atypical cells**\n‚Ä¢ **Hyperchromasia**\n\n**CHARACTERISTICS:**\n‚Ä¢ **Central location** (hilar) ‚≠ê\n‚Ä¢ **Cavitation** common ‚≠ê\n‚Ä¢ **Strong smoking association** ‚≠ê‚≠ê‚≠ê\n\n**LUNG CANCER & HYPERCALCEMIA:**\n‚Ä¢ **SCC:** PTH-rP ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Small cell:** SIADH (NOT hypercalcemia)\n‚Ä¢ **Adenocarcinoma:** Hypertrophic osteoarthropathy\n\n**TREATMENT:**\n‚Ä¢ **Surgical resection** (if resectable)\n‚Ä¢ **Chemotherapy + RT**\n\nüí° **KEY:** **Smoker + Lung cancer + Hypercalcemia = Squamous cell carcinoma (PTH-rP)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-196",
    subjectId: "pathology",
    chapterId: "neet-pg-2023",
    question: "An elderly male went for a medical examination. Laboratory investigations showed a marked elevation of lymphocytes with marked leukocytosis. The peripheral smear of the patient is given below. What is the appropriate next step for this patient? r e d d a L",
    options: [
      "Stem cell transplantation p",
      "Bone marrow biopsy",
      "Flow cytometry",
      "Start high-dose chemotherapy r",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Flow cytometry (Option C)**\n\nüî¨ **CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - DIAGNOSIS:**\n\n**THIS CASE:**\n‚Ä¢ **Elderly male** ‚≠ê (CLL = disease of elderly)\n‚Ä¢ **Marked lymphocytosis** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Marked leukocytosis**\n‚Ä¢ **Peripheral smear:** (From image) Likely smudge cells\n\n**NEXT STEP:** **FLOW CYTOMETRY** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**FLOW CYTOMETRY:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Diagnostic test for CLL**\n‚Ä¢ **Immunophenotyping** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Confirms diagnosis**\n‚Ä¢ **CD5+, CD19+, CD23+** ‚≠ê‚≠ê‚≠ê (characteristic)\n‚Ä¢ **CD20+ (dim)**\n\n**CLL FEATURES:**\n‚Ä¢ **Smudge cells** (Gumprecht shadows) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Mature-looking lymphocytes**\n‚Ä¢ **Most common adult leukemia**\n‚Ä¢ **Incidental finding** often\n\n**DIAGNOSTIC CRITERIA:**\n‚Ä¢ **Lymphocyte count >5000/ŒºL** for ‚â•3 months\n‚Ä¢ **Flow cytometry** confirming clonal B cells\n\n**WHY NOT OTHERS:**\n‚Ä¢ **Bone marrow biopsy:** NOT needed for diagnosis (done for staging)\n‚Ä¢ **Chemo:** NOT started without confirmation\n‚Ä¢ **Stem cell transplant:** Advanced management (NOT first step)\n\nüí° **KEY:** **Elderly + Lymphocytosis ‚Üí Flow cytometry (confirm CLL)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-198",
    subjectId: "pathology",
    chapterId: "neet-pg-2023",
    question: "Question 198 - [Content needs manual review]",
    options: [
      "Option 1",
      "Factors XI and XII",
      "Von Willebrand factor",
      "Lupus anticoagulant",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Option 1**\n\nüî¨ Detailed explanation to be added.",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page98_img51.jpeg",
    year: 2023
  },{
    id: "neet-pg-2023-199",
    subjectId: "pathology",
    chapterId: "neet-pg-2023",
    question: "A chronic smoker who worked in a cement factory for 20 years developed mesothelioma. The association is likely to be due to ________.",
    options: [
      "Silicosis",
      "Asbestosis e",
      "Coal workers' pneumoconiosis",
      "Bagassosis",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Asbestosis (Asbestos exposure) (Option B)**\n\nüî¨ **MESOTHELIOMA & ASBESTOS:**\n\n**THIS CASE:**\n‚Ä¢ **Cement factory worker** ‚≠ê‚≠ê‚≠ê (20 years)\n‚Ä¢ **Developed mesothelioma** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Chronic smoker** ‚≠ê\n\n**ASBESTOS EXPOSURE:** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**MESOTHELIOMA:**\n‚Ä¢ **Malignant tumor** of pleura/peritoneum\n‚Ä¢ **STRONGLY associated with ASBESTOS** ‚≠ê‚≠ê‚≠ê (80-90% cases)\n‚Ä¢ **Latency period:** 20-40 years ‚≠ê\n\n**ASBESTOS-RELATED DISEASES:**\n1. **Asbestosis** (pulmonary fibrosis) ‚≠ê\n2. **Mesothelioma** ‚≠ê‚≠ê‚≠ê **(MOST SPECIFIC)**\n3. **Lung cancer** (synergistic with smoking) ‚≠ê\n4. **Pleural plaques** (benign)\n\n**OCCUPATIONS AT RISK:**\n‚Ä¢ **Construction** workers ‚≠ê\n‚Ä¢ **Shipyard** workers\n‚Ä¢ **Cement factory** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Insulation** workers\n\n**WHY NOT OTHERS:**\n‚Ä¢ **Silicosis:** Coal mines, sandblasting (NOT mesothelioma)\n‚Ä¢ **Coal workers' pneumoconiosis:** Coal miners\n‚Ä¢ **Bagassosis:** Sugarcane workers (extrinsic allergic alveolitis)\n\nüí° **KEY:** **Mesothelioma = Asbestos exposure (cement factory)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page98_img52.jpeg",
    year: 2023
  }
];

export default questions;

// Helper function to get questions by chapter
export function getQuestionsByChapter(chapterId: string): Question[] {
  return questions.filter(q => q.chapterId === chapterId);
}

// Export question count
export const questionCount = questions.length;
